Smart investing starts with good data. Stoxcraft scores are analytical tools, not buy or sell recommendations. This article is for informational purposes only. Make sure any investment decision fits your own situation. When in doubt, talk to a financial advisor.
The strongest stock recoveries don't begin when everything is fixed. They begin when the fundamentals have stabilized and the price still reflects past pain. That gap between reality and perception is where the opportunity hides.
Novo Nordisk (NVO), Nike (NKE), UnitedHealth Group (UNH), and The Trade Desk (TTD) each sit 30% to 65% below their all-time highs. Each has shown measurable signs of fundamental improvement that the current price doesn't fully capture.
NVO, NKE, UNH, and TTD stock results in numbers
The data across these four names tells a consistent story: strong or improving fundamentals, brutal price performance, and trend signals that are either turning or not yet supportive.
Novo Nordisk's oral Wegovy delivered 16.6% average weight loss in a 64-week trial, matching the injectable version, while the stock sits 60% below its 2024 peak. Nike's Q3 fiscal 2026 revenue of $11.3B beat estimates, with North America returning to positive all-channel growth for the first time in two years. UnitedHealth's Q1 2026 EPS of $7.23 came in 10% above the $6.58 consensus, and management raised full-year guidance despite the ongoing DOJ investigation. The Trade Desk posted $689M in Q1 2026 revenue, up 12% year over year, with adjusted EBITDA margins at 30% and customer retention above 95%.
In each case, the business didn't break. The stock did.
What the Stoxcraft scores say about NVO, NKE, and TTD
Three of the four stocks carry active Stoxcraft scores. UNH is not currently in the Stoxcraft universe, so the analysis for that name relies on public fundamentals only.
Health and performance: where the fundamentals stand
NVO holds a health score placing it in the top 10% of all healthcare companies in the Stoxcraft universe, anchored by exceptional free cash flow generation and operating margins well ahead of most European pharma peers. TTD ranks in the top 20% of communication services on health, driven by a capital-light business model with 30% EBITDA margins and decade-long 95% customer retention. NKE sits near the sector median on health, with strong cash reserves of $6.66B but ongoing margin pressure from the inventory reset.
The performance picture is the inverse. All three stocks rank in the bottom third of the Stoxcraft universe on price performance, reflecting drawdowns of 55% to 65% from their respective highs. The business quality hasn't matched the price destruction.
Risk and technical signals
NVO and TTD both carry elevated risk scores, consistent with stocks that have experienced severe drawdowns and high volatility. NKE's risk score sits in the moderate range, which is lower than many expect for a stock this beaten down. Its beta is relatively contained, and the defensive-consumer profile limits the fragility reading.
Technical signals diverge sharply. TTD's RSI has recovered from oversold territory, the MACD has turned positive, and the stock is closing the gap to its 52-week high. NVO's short-term picture remains fully bearish: RSI below 50, negative MACD, far from its 52-week high. NKE sits between those two, with RSI recovering from deeply oversold levels and the MACD beginning to flatten.
NVO, NKE, TTD, and UNH vs. their sectors
TTD leads the group on sector-relative scoring. Its 4-star overall rating makes it one of the highest-rated communication services stocks in the Stoxcraft universe. NVO's 2-star rating reflects the collision between top-tier healthcare fundamentals and one of the worst performance records in the universe right now. NKE's 3-star rating correctly captures a business mid-turnaround with real near-term catalysts in the 2026 FIFA World Cup. UNH sits outside the universe, but its $17.7B in annual free cash flow and a Q1 2026 earnings beat suggest mean-reversion potential that the current price may not reflect.
The score pattern to watch across all four names
All four stocks fit the Turnaround Candidate archetype: weak or recovering performance scores, improving or stabilizing health fundamentals, and trend signals that are either beginning to shift or not yet supportive. The business quality is ahead of the price action in each case.
TTD is the furthest along in the recovery. The trend signal is improving, the entry signal is approaching Buy territory, and the fundamental quality never deteriorated despite the stock's collapse.
NVO has the strongest underlying business of the four, but the timing isn't there yet. The trend needs to turn before the entry signal improves. Patience is the correct framing.
NKE has a real catalyst in summer 2026. The World Cup, a stabilizing North America, and early signs of gross margin recovery could move the overall rating toward 3.5 stars within two quarters.
Which of these four setups is most aligned right now
According to Nasdaq market data, TTD's technical picture has been improving steadily since early 2026. For investors looking at all four names, it's the setup where fundamentals and timing are most aligned: a 4-star rating, a business that never broke, and a trend signal that is now working in the same direction as the long-term fundamental case.
NVO and NKE require more patience. UNH requires more information on the DOJ outcome. TTD requires conviction that the ad-tech market hasn't structurally shifted away from its model, which the retention data suggests it hasn't.
For more on how these types of stocks are identified, see stocks with comeback potential and the broader context in the 5 biggest forces shaping the stock market.
